Abstract This cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr. João Machado, Natal, Rio Grande do Norte, Brazil. Socioeconomic, sociodemographic, and clinical variables were compared. The QoL Scale validated for Brazil (QLS-BR) was used to evaluate QoL, and adverse effects were assessed using the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. Data were analyzed using the v 2 test and Student's t test, with a significance level of 5 %. Patients in both drug groups showed severe impairment in the occupational domain of the QLS-BR. Global QLS-BR scores indicated impairment among risperidone users and severe impairment among olanzapine users. The most significant side effects were associated with risperidone, including asthenia/lassitude/fatigue, somnolence/sedation, paresthesia, change in visual accommodation, increased salivation, diarrhea, orthostatic posture, palpitations/ tachycardia, erythema, photosensitivity, weight loss, galactorrhea, decreased sexual desire, erectile/orgasmic dysfunction, vaginal dryness, headache, and physical dependence. QoL was impaired in patients using olanzapine and in those using risperidone. Risperidone use was associated with psychic, neurological, and autonomous adverse effects and other side effects.
Introduction
The ability of antipsychotic drugs to reduce psychotic symptoms via the blockade of dopamine D2 receptors has been well established [1] . Numerous antipsychotic agents are currently available for the treatment of schizophrenia, but residual symptoms and troublesome side effects continue to be a major clinical problem during treatment with conventional antipsychotics. In contrast, atypical antipsychotic drugs have fewer extrapyramidal side effects and yield more favorable social outcomes in patients with schizophrenia [2] . The primary advantage of atypical antipsychotics is their superior side effect profile, particularly with regard to extrapyramidal symptoms [2] . Systematic reviews have shown that treatment with atypical antipsychotics results in significantly greater health improvements than treatment with conventional antipsychotics, mainly regarding motor side effects, which significantly impair patients' quality of life (QoL) [3] .
QoL is a key outcome variable in the treatment of schizophrenia, and the importance of evaluating it has been increasingly recognized in patient care and clinical research [4] [5] [6] . Atypical antipsychotics have been shown to be superior to typical antipsychotics in improving QoL in patients with schizophrenia [6] .
However, earlier questionnaire-based research has focused on QoL from a physician's perspective, and few studies have compared QoL in patients undergoing pharmacotherapy with different types of atypical antipsychotic. The QoL Scale (QLS) developed by Heinrichs et al. [7] aims to ''objectively'' assess QoL in patients with schizophrenia [8, 9] .
By using a QLS validated for Brazil (QLS-BR) [10] , this study aimed to compare QoL and adverse effects in patients diagnosed with schizophrenia who were treated with olanzapine or risperidone.
Materials and Methods

Study Design and Subjects
The study was conducted in the Hospital Dr. João Machado, Natal, Rio Grande do Norte (RN), Brazil, which provides healthcare to 4,500 people. The hospital's Specialized Component of Pharmaceutical Assistance (SCPA) is a primary treatment and monitoring center in the state of RN for patients with schizophrenia and other severe mental disorders, primarily those who have not responded to first-generation antipsychotics (e.g., haloperidol) [11] .
This cross-sectional study was conducted with adult patients diagnosed with schizophrenia according to the International Classification of Diseases (ICD)-10 and Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV [12] criteria who began treatment with a atypical antipsychotic [olanzapine (10 mg) or risperidone (4 mg)] at the SCPA. The antipsychotic drug and dosage were prescribed entirely at the physician's discretion, but these two drugs are prescribed to approximately 90 % of patients at the SCPA [11] . The use of atypical antipsychotic is justified by decree 846 of November 6, 2002, for refractory schizophrenia, which provides that in the case of risperidone failure or contraindication, clozapine is a treatment option. Moreover, if clozapine is unable to be prescribed, then quetiapine, ziprasidone, or olanzapine are recommended. Although clozapine is considered as the second option after risperidone, the need for weekly hematological control limits its use in Brazil [13] .
Individuals over 18 years old who used one of these atypical antipsychotics for at least 1 year were considered for inclusion in the study. Participants and their family members signed the Informed Consent Protocol No. 001/06-CEP/UFRN. The study was conducted in accord with the Declaration of Helsinki [14] .
Sample Size Calculation
In 2011, 4,500 patients at the ambulatory service of the Hospital João Machado received atypical antipsychotics (olanzapine, 53.4 %; risperidone, 32 %). To calculate the sample size, we used a 95 % confidence interval and a 10 % tolerable sampling error. Considering the finite population and the prevalence of risperidone use, the following formula was used [15] :
where n is the sample size, z a/2 is the confidence interval, P is the prevalence, N is the population, and e is the tolerable sampling error. The calculated sample size was 115 patients: 54 individuals using olanzapine and 61 using risperidone. After setting the sample size, patients were randomly sampled from the hospital population. Enrolled patients were identified by a number and a random drawing was conducted. After the drawing, the first contact with a patient was conducted by telephone so that only those patients who wished to participate and could attend the hospital were selected together. In case of impossibility of participation, a new lottery was held.
Data Collection
Sociodemographic variables (age, sex, marital status, socioeconomic status) were assessed using a structured questionnaire developed and validated for the. Data about diagnosis and antipsychotic drug use were also collected. Adverse events were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale [16] , which rates symptom severity and the perception or assessment that a symptom is a side effect. This scale evaluates the side effects related to the use of antipsychotic, the UKU is divided into three sections: (1) psychiatric symptoms (10 items), (2) neurological symptoms (8 items) and (3) autonomic symptoms (10 items). The severity of each item is based on levels 0-3.
QoL was assessed using the QLS-BR [10] . The QLS developed by Heinrichs et al. [7] is based on semi-structured interviews and is considered a gold standard research instrument for assessing QoL in patients with schizophrenia from a physician's perspective, providing information on patients' symptoms and functioning [10] . Briefly, the QLS comprises 21 items in three domains: social, occupational, and intrapsychic/interpersonal relationships. Each item is scored using a seven-point Likert-style structure, where scores of 5-6 indicate normal/unaltered functioning, scores of 2-4 indicate impairment in some aspect of the patient's life, and scores of 0-1 indicate strong impairment for the item considered.
The social networking items of the QLS evaluate the quality and frequency of contact with relatives and friends, and include questions regarding active or passive participation and reduction in social networking or complete reclusion. The occupational items are related to formal and informal work, including questions related to functioning, skills, opportunities, satisfaction with occupational performance, and distribution/use of time. Finally, the intrapsychic function and interpersonal relationship items evaluate the frequency of social contact, the ability to make complex judgments, and the capacity for intimacy. Some items assess cognitive functioning and affectivity, which are considered core aspects of schizophrenia. Other items evaluate the subject's life goals, curiosity, and involvement in common social activities.
The mean scores of each group (olanzapine and risperidone users) were used to classify QoL into three categories: very impaired (0-1.99), impaired (2.00-4.99), and unchanged (5.00-6.00).
Data Analysis
Socioeconomic, sociodemographic, and clinical variables were compared between the olanzapine and risperidone groups using the v 2 test, and QLS-BR and UKU Side Effect Rating Scale scores were compared using Student's t test. p \ 0.05 was considered significant.
Results
All patients who were asked to participate provided informed consent and were included in the analysis. Fifty-four (46.96 %) participants were using olanzapine and 61 (53.04 %) were using risperidone.
In accordance with Rule 846, which regulates the use of atypical antipsychotics in Brazil, candidates for the use of these medicines were patients refractory to typical antipsychotics or those experiencing typical side effects [13] . A larger proportion of patients used risperidone than olanzapine in the ambulatory service of our hospital.
The sociodemographic profiles of patients using olanzapine and risperidone are presented in Tables 1 and 2 . Participants taking olanzapine were more commonly men (p \ 0.004), but no other sociodemographic difference was observed between groups. All participants had used olanzapine or risperidone for [12 months (p \ 0.002).
Participants in both groups showed impaired QoL, as reflected by domain and global QLS-BR scores (Table 3 ). Significant differences were found between groups in scores items of the social domain: active friendship with lower scores for olanzapine (p \ 0.043) and social withdrawal (p \ 0.022) with lower scores for risperidone (Table 3) .
We observed the following adverse effects of risperidone (Table 4) 
Discussion
Recent studies have focused on the comparable effectiveness and short-and long-term side effect profiles of atypical antipsychotics, finding evidence for differing effectiveness among drugs [17] [18] [19] [20] .
In contrast to previously published data [21, 22] , our study found that olanzapine and risperidone use was not sufficient to improve patients' QoL. One explanation for this discrepancy may be related to family income; in our study sample, 79.6 % of olanzapine users and 73.8 % of risperidone users had incomes less than or equal to twice the minimum wage in Brazil (US$ 683.51.85). Another potentially confounding issue is occupation; 88.9 % of olanzapine users and 90.2 % of risperidone users in our sample did not work. According to Leão and Barros [23] , social exclusion is a problematic occupational issue in people with severe and persistent mental disorders, due mainly to the stigmatization of the disease and the prevalence of unemployment, even among those with ''normal'' productivity and competitiveness. Although the Brazilian government subsidizes patients' purchase of these antipsychotic drugs, pharmacological treatment alone is not sufficient to achieve good QoL; thus, a need exists for the design and implementation of public policies that improve social inclusion for patients with schizophrenia. The Brazilian government operates Centers for Psychosocial Care, which are intended to provide clinical services to improve social reintegration of antipsychotic drug users through work and leisure activities, and the strengthening of family and community ties [23] .
We observed different adverse events in patients treated with risperidone. These results are concordant with those of other studies, which reported a significantly higher incidence of EPSs, hyperprolactinemia, and sexual dysfunction in patients taking risperidone than in those taking olanzapine [24, 25] . Stroup et al. [26] found lower rates of insomnia in patients receiving olanzapine (13 %) and quetiapine (16 %) than in those receiving risperidone (23 %) or ziprasidone (31 %). Patients receiving risperidone experienced higher rates of adverse effects involving sexual function (29 %) relative to the other groups (11-17 %). Risperidone was also associated with higher rates of gynecomastia or galactorrhea (5 %) compared with the other groups (\1 %). No difference was found in the incidence of EPSs, akathisia, or abnormal movements among the drugs, as reflected by severity ratings or reasons for discontinuing treatment [26] . Ciudad et al. [27] found adverse events related to the sexual dysfunction were significantly more frequently reported by risperidone patients versus with olanzapine. The most frequent sexual adverse events were libido decreased and sexual dysfunction [27] . Based on UKU results, we observed the main symptoms related to altered prolactin levels in response to risperidone therapy, such as galactorrhea, reduced sexual desire, erectile/ orgasmic dysfunction, and vaginal dryness.
Conclusions
We found a significant prevalence of psychic, neurological, autonomous adverse effects and other side effects among risperidone users. QLS-BR results indicated that patients taking risperidone and olanzapine had impaired or very impaired QoL. Many patients in both groups had low household incomes and were unemployed; thus, the effects of these antipsychotic agents appear to have been masked by aggravating social and economic situations. 
